NCT02212535View on ClinicalTrials.gov

Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 15, 2016

Primary Completion Date

April 4, 2017

Study Completion Date

September 27, 2017

Conditions
Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia
Interventions
DRUG

Plerixafor

0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis

Trial Locations (1)

75015

Hôpital Necker - Enfants Malades, Paris

All Listed Sponsors
collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02212535 - Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients | Biotech Hunter | Biotech Hunter